In:
Experimental Dermatology, Wiley, Vol. 27, No. 2 ( 2018-02), p. 188-190
Abstract:
While mycosis fungoides ( MF ) is typically an indolent malignancy, it may infrequently undertake an aggressive course. We used proteomic analyses to identify a biomarker of the aggressive course of MF . Results of this investigation demonstrated that PARP ‐1, heat‐shock protein family A (Hsp70) member 1 like ( HSAP 1L), Hsp70 member 1A ( HSPA 1A), ATP ‐depending RNA helicase ( DDX 17) and the α‐isoform of lamina‐associated polypeptide 2 ( TMPO ) had higher expression in aggressive disease versus non‐aggressive. Moreover, PARP ‐1 was overexpressed in patients with early stage of MF who developed later an aggressive disease. PARP ‐1 was evaluated as a new target for therapy, demonstrating the selective dose‐dependent cytotoxic effect of PARP inhibitors on Sézary cells in comparison with non‐malignant lymphocytes. In conclusion, we believe that PARP ‐1 may serve not only as a biomarker at initial biopsies for a disease that may become aggressive but also as a new therapeutic target of advanced MF and Sézary syndrome.
Type of Medium:
Online Resource
ISSN:
0906-6705
,
1600-0625
DOI:
10.1111/exd.2018.27.issue-2
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2026228-0